Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Prospective Randomized Open Label Study of the Treatment of Therapy-Associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium - (Loop)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2007 by Philipps University Marburg Medical Center.
Recruitment status was:  Not yet recruiting
Maros Arzneimittel GmbH
Information provided by:
Philipps University Marburg Medical Center Identifier:
First received: March 6, 2007
Last updated: August 31, 2007
Last verified: August 2007
Therapy-associated diarrhea during radiation therapy of small pelvis (including enteritis as a result of radiation therapy and enteritis as a result of radiation- and chemotherapy) is a common problem in multimodal cancer therapy. We investigate the therapeutic effect of either loperamide or tinctura opii in therapy- associated diarrhea in patients who receive radiation therapy of the small pelvis with or without chemotherapy.

Condition Intervention Phase
Drug: Tinctura opii
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Prospective Randomized Open Label Study of the Treatment of Therapy-Associated Diarrhea During Percutaneous Radiation Therapy of the Small Pelvis. - Comparison of Loperamide and Tincture of Opium

Resource links provided by NLM:

Further study details as provided by Philipps University Marburg Medical Center:

Primary Outcome Measures:
  • In this study efficacy of loperamide and tincture of opium is linked to the respective proportions of patients where diarrhoea of grade > 2 is successfully averted during (cancer) therapy.
  • Should diarrhoea of grade > 2 occur despite the respective drug treatment, the corresponding medicament is assessed as inefficacious in that case.

Secondary Outcome Measures:
  • Scores from the EORTC-QLQ-C30
  • Body composition data (BMI, proportions of fat and water

Estimated Enrollment: 200
Study Start Date: September 2007

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Age ≥ 18 years
  • Patients who will undergo a percutaneous radiation therapy in the area of the small pelvis. This includes patients with following malignancies: rectal carcinoma, prostate carcinoma, endometrial carcinoma, cervix carcinoma.
  • Diarrhea grade 1 and grade 2 (Classification NCI-CTCAE Version 3.0)
  • ECOG-Grade 0-2
  • Enlightenment and written declaration of consent to the participation.

Exclusion Criteria:

  • Pregnant patients or patients in lactation period.
  • Severe dysfunction of liver or kidneys
  • Injury or illness of brain e.g. increased intracranial pressure, cerebral arteriosclerosis
  • Epilepsy
  • Hypersensitivity to components of loperamide or tincture of opium
  • Ileus
  • Toxic megacolon
  • Pseudomembranous colitis/ antibiotic-associated colitis
  • Diarrhea associated with fever and bloody stools
  • Acute increase of colitis ulcerous or bacterial colitis caused by invasive pathogenes
  • Severe respiratory dysfunction or severely limited lung function e.g. bronchial asthma, bronchitis
  • Dysfunctional draining of biliary area, biliary colics.
  • Concomitant or earlier addiction of alcohol or opiates
  • Severe heart disease
  • Pheochromocytoma
  • Acute hepatic porphyria
  • Cor pulmonale
  • Morbus Addison
  • Severe hypothyroidism
  • Organisational problems or circumstances which prevent a complete collection of required data
  • Artificial anus
  • Participation in a clinical trial within the last 30 days before involvement
  • Participation in an other clinical trial at the same time
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00444093

Sponsors and Collaborators
Philipps University Marburg Medical Center
Maros Arzneimittel GmbH
Principal Investigator: Michael Bieker, MD center of radiology, departement of radiation therapy, clinical center Giessen and Marburg
  More Information Identifier: NCT00444093     History of Changes
Other Study ID Numbers: 2006-002948-28
Study First Received: March 6, 2007
Last Updated: August 31, 2007

Keywords provided by Philipps University Marburg Medical Center:
radiation therapy
supportive therapy
therapy associated diarrhea
therapy associated enteritis
radiation therapy of the small pelvis

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Gastrointestinal Agents processed this record on May 25, 2017